Drug Target Review – Issue 1 2020
Posted: 23 March 2020 | Drug Target Review | No comments yet
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
Included in this issue:
- ASSAYS
In vitro platforms for de-risking nephrotoxicity during drug development
Colin Brown, Newcells Biotech
Sandy Primrose, Newcells Biotech - LAB AUTOMATION
Scientific data management: the core of quality
Roberto Castelnovo, NL42 Consulting - ANTIBODIES
Not everyone loves surprises: know your ADC’s critical quality attributes
Omar Lamm, MilliporeSigma
Martin De Cecco, Merck - CELL LINE DEVELOPMENT
Cell line development for therapeutic proteins – current perspectives and future opportunities
Dr Jonathan H Dempsey, Dempsey Consulting - INFORMATICS
How labs become AI ready with advanced informatics infrastructures
Unjulie Bhanot, IDBS
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Antibodies, Artificial Intelligence, Assays, Drug Targets, Genomics, Immunooncology, In Vitro, Informatics, Lab Automation, Research & Development, Targets, Technology, Therapeutics
Related organisations
Thermo Fisher Scientific